The rising popularity of weight loss drugs is a key reason healthcare company Eli Lilly (NYSE: LLY) has been soaring in value ...

Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech ...

Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor ...

Eli Lilly and Company (NYSE:LLY) is one of the best long term growth stocks to buy according to hedge funds. On January 9, ...

Eli Lilly’s Mounjaro is the only dual drug on the market, targeting GLP-1 and GIP. Doctors say that Mounjaro is also more ...

One of the major promises of artificial intelligence (AI) is its role in speeding up drug discovery. AI can process massive ...

These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

Abivax stock (EPA: ABVX) surged roughly 30% in early Paris trading Monday after French media reported that US pharmaceutical giant Eli Lilly was preparing a €15 billion ($17.5 billion) acquisition ...

French newspaper La Lettre said the Paris-based biotech – which is listed on the Nasdaq – has been on Lilly's radar after ...